LONDON, May 25, 2023 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces an update to its intellectual property (“IP“) portfolio, demonstrating significant progress already made by the Company in 2023. Small Pharma aims to…


Previous articlePT411 – The Humanity of Healthcare Professionals, Ancient Psychedelic Use, and Breaking the Cycle of Colonialism
Next articleData Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of COMP360 Psilocybin Therapy to be Presented at ASCO 2023